Trypanosomiasis, African
14
1
1
9
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 64/100
21.4%
3 terminated out of 14 trials
75.0%
-11.5% vs benchmark
21%
3 trials in Phase 3/4
44%
4 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (14)
Pharmacokinetic, Efficacy, Safety and Tolerability Study of a Single Dose of Acoziborole in g-HAT Paediatric Patients
Efficacy and Safety of Acoziborole (SCYX-7158) in Patients With Human African Trypanosomiasis Due to T.b. Gambiense
Safety and Tolerability Study of Acoziborole in g-HAT Seropositive Subjects
Fexinidazole in Human African Trypanosomiasis Due to T. b. Rhodesiense
Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage
Screen and Treat Implementation for HAT Control
DDI Study of Single Oral Dose of Acoziborole With Sequential Co-administration of Midazolam and Dextromethorphan
Multiple Dose Study to Evaluate Security, Tolerance and Pharmacokinetic of Fexinidazole (Drug Candidate for Human African Trypanosomiasis) Administered With a Loading Dose and With Food
Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African Trypanosomiasis
Bioequivalence Study - Reference Clinical Fexinidazole Tablet Versus Proposed Market Formulation
Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the SCYX-7158
A Trial of DB289 for the Treatment of Stage I African Trypanosomiasis
Eflornithine + Nifurtimox Late-Stage Human African Trypanosomiasis (HAT)in West Nile, Uganda
Randomized Clinical Trial of Three Drug Combinations for Late-Stage Gambiense Human African Trypanosomiasis